**Supplementary Table 2. Current meta-analyses on the correlation between proton pump inhibitors and COVID-19**

|  |  |  |
| --- | --- | --- |
| Publication | Number of included literatures | Impact on patients with COVID-19 |
| Hariyanto TI et al.1 | 6 | The use of PPIs was associated with increased risks of severity (RR 1.35, 95% CI 1.11–1.63, *I*2 = 45%) and mortality (RR 1.72, 95% CI 1.02–2.89, *I*2 = 66%). |
| Kow CS et al.2 | 5 | The use of PPIs was associated with increased odds for a severe or fatal course of COVID-19 (OR 1.46, 95% CI 1.34–1.60). |
| Li GF et al.3 | 16 | The current use of PPIs was associated with increased susceptibility to SARS-CoV-2 infection (OR 1.33, 95% CI 0.86-2.07, *I*2 = 97%) or severe outcomes of COVID-19 (OR 1.67, 95% CI 1.19-2.33, *I*2=63%); The past use of PPIs was not associated with these adverse outcomes.  |
| Kamal F et al.4 | 7 | The use of PPIs was not associated with increased risks of severe disease (RR 1.95; 95% CI 0.94–4.07, *I*2=96%). The use of PPIs was associated with increased risks of mortality (OR 2.12, 95% CI 1.29–3.51, *I*2=96%). |
| Toubasi AA et al.5 | 6 | The use of PPIs was not associated with increased odds of COVID-19 development (OR 1.19, 95%CI 0.62-2.28, *I*2=99%). The use of PPIs was associated with increased odds of mortality (OR 1.67; 95% CI: 1.41-1.97, *I*2=0%). |
| Pranata R et al.6 | 12 | The use of PPIs was not associated with increased susceptibility to SARS-CoV-2 infection (OR 1.56, 95% CI 0.48-5.05, *I*2=99%); The use of PPIs was associated with increased composite poor outcome (OR 1.85, 95%CI 1.13-3.03, *I*2=90%). |
| Zippi M et al.7 | 5 | The use of PPIs was not associated with increased risk of severe events (OR 1.65, 95%CI 0.62-4.35, *I*2 = 96%) or mortality (OR 1.77, 95%CI 0.62-5.03, *I*2 = 89%). |
| Israelsen SB et al.8 | 12 | The use of PPIs was not associated with increased susceptibility to SARS-CoV-2 infection (OR 1.00, 95% CI 0.74-13.43, *I*2 = 98%) or mortality (RR 1.33, 95%CI 0.71-2.48, *I*2 = 84%). |
| Yan C et al.9 | 8 | The use of PPIs was not associated with increased susceptibility to SARS-CoV-2 infection (OR 1.64, 95% CI 0.54-5.00, *I*2 = 100%) or mortality (OR 1.91, 95%CI 0.86-4.24, *I*2 = 73%); The use of PPIs was associated with increased risk of severe disease (OR 1.67, 95%CI 1.37-2.02, *I*2 = 67%). |